PharmaShots | Incisive News in 3 Shots

Subscribe Now

RMS

Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS

Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS

April 19, 2021

Novartis Reports Acceptance of Ofatumumab's (OMB157) sBLA from the US FDA and EMA to Treat Relapsing Forms of Multiple Sclerosis (RMS)

Novartis Reports Acceptance of Ofatumumab's (OMB157) sBLA from the US FDA and EMA to Treat Relapsing Forms of Multiple Sclerosis (...

February 24, 2020

Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)

Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)

March 26, 2019

Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

October 11, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us